iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Growth in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 307,800 shares, an increase of 123.5% from the September 30th total of 137,700 shares. Based on an average daily trading volume, of 120,500 shares, the short-interest ratio is currently 2.6 days. Currently, 3.4% of the company’s stock are sold short.

iBio Trading Up 1.8 %

Shares of NYSEAMERICAN:IBIO traded up $0.05 during trading on Friday, reaching $2.85. The company had a trading volume of 88,892 shares, compared to its average volume of 1,256,904. iBio has a 12 month low of $1.02 and a 12 month high of $6.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.